![[Biolojic in Business Wire] Aulos Bioscience publicizes FDA clearance of IND Utility for AU-007, a novel immunotherapy for the therapy of strong tumors](https://blog.ourcrowd.com/wp-content/uploads/2021/11/business_wire-web.png "[Biolojic in Business Wire] Aulos Bioscience publicizes FDA clearance of IND Utility for AU-007, a novel immunotherapy for the therapy of strong tumors")
LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology firm working to revolutionize most cancers care by means of the event of probably best-in-class IL-2 therapeutics, right now introduced that the U.S. Meals and Drug Administration (FDA) has cleared its Investigational New Drug (IND) software for AU-007, a monoclonal antibody computationally designed by Biolojic Design. AU-007 leverages a singular strategy to harnessing the facility of interleukin-2 (IL-2) to eradicate strong tumors. That is the primary time {that a} computationally designed human monoclonal antibody has been cleared for human trials in the USA.
